Patents by Inventor Julie A. Wurster

Julie A. Wurster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
    Patent number: 9758509
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: September 12, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Xialing Guo, Zhen Zhu, Thomas C. Malone, Julie Wurster
  • SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS
    Publication number: 20170174664
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: March 6, 2017
    Publication date: June 22, 2017
    Inventors: Xialing Guo, Zhen Zhu, Thomas C. Malone, Julie Wurster
  • Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
    Patent number: 9657005
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: May 23, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Xialing Guo, Zhen Zhu, Thomas C. Malone, Julie Wurster
  • Substituted nicotinamide derivatives as kinase inhibitors
    Patent number: 9567324
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: February 14, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Sougato Boral, Shimiao Wang, Thomas C. Malone, Julie Wurster, Jie Shen, Michael Robinson
  • SUBSTITUTED NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20160194311
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: March 14, 2016
    Publication date: July 7, 2016
    Inventors: Sougato Boral, Shimiao Wang, Thomas Malone, Julie Wurster, Jie Shen, Michael Robinson
  • Kinase inhibitors
    Patent number: 9365575
    Abstract: The present invention relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein variables R, Ar, X, and Ar1 and n are as defined herein. The compounds are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: June 14, 2016
    Assignee: Allergan, Inc.
    Inventors: Thomas C. Malone, Julie A. Wurster, Clarence Eugene Hull, III
  • Kinase inhibitors
    Patent number: 9321766
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: April 26, 2016
    Assignee: Allergan, Inc.
    Inventors: Julie Wurster, Richard Yee, Clarence Eugene Hull, III, Thomas C. Malone
  • PIPERIDYLPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASE INHIBITORS AND OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2
    Publication number: 20160102088
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The compounds of Formula I are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: October 10, 2014
    Publication date: April 14, 2016
    Inventors: Julie A. Wurster, Thomas C. Malone, Clarence Eugene Hull, III, Sandhya Rao, Rong Yang, Richard Yee
  • KINASE INHIBITORS
    Publication number: 20160096832
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: October 6, 2014
    Publication date: April 7, 2016
    Inventors: Julie Wurster, Richard Yee, Clarence Eugene Hull III, Thomas C. Malone
  • Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
    Patent number: 9296747
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The compounds of Formula I are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: March 29, 2016
    Assignee: Allergan, Inc.
    Inventors: Julie A. Wurster, Thomas C. Malone, Clarence Eugene Hull, III, Sandhya Rao, Rong Yang, Richard Yee
  • Substituted dialkyl(oxido)-lambda4-sulfanylidene nicotinamide derivatives as kinase inhibitors
    Patent number: 9266869
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: February 23, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Shimiao Wang, Thomas Malone, Julie Wurster, Jie Shen, Michael Robinson
  • SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20150166521
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: December 10, 2014
    Publication date: June 18, 2015
    Inventors: Sougato Boral, Shimiao Wang, Thomas Malone, Julie Wurster, Jie Shen, Michael Robinson
  • SUBSTITUTED NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20150166518
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: December 10, 2014
    Publication date: June 18, 2015
    Inventors: Sougato Boral, Shimiao Wang, Thomas Malone, Julie Wurster, Jie Shen, Michael Robinson
  • 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
    Patent number: 8969583
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R1, R2, R3, n, X1, X2, L1, and L2 are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: Thomas C. Malone, C. Eugene Hull, Sougato Boral, Julie A. Wurster, Michael R. Robinson, Jeffrey L. Edelman
  • SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS
    Publication number: 20150018310
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: September 29, 2014
    Publication date: January 15, 2015
    Inventors: Xialing Guo, Zhen Zhu, Thomas C. Malone, Julie Wurster
  • Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
    Patent number: 8865682
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: October 21, 2014
    Assignee: Allergan, Inc.
    Inventors: Xialing Guo, Zhen Zhu, Thomas C. Malone, Julie Wurster
  • KINASE INHIBITORS
    Publication number: 20130310394
    Abstract: The present invention relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein variables R, Ar, X, and Ar1 and n are as defined herein. The compounds are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: May 20, 2013
    Publication date: November 21, 2013
    Applicant: Allergan, Inc.
    Inventors: Thomas C. Malone, Julie A. Wurster, Clarence Eugene Hull, III
  • Sulfoximines as kinase inhibitors
    Patent number: 8558002
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: October 15, 2013
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Shimiao Wang, Julie A. Wurster
  • KINASE INHIBITORS
    Publication number: 20130267497
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Application
    Filed: June 3, 2013
    Publication date: October 10, 2013
    Inventors: Lon T. Spada, Jane-Gou Shiah, Patrick M. Hughes, Thomas C. Malone, Gerald W. Devries, Jeffrey L. Edelman, Julie A. Wurster, Xialing Guo, Sougato Boral
  • Heteroaryl dihydroindolones as kinase inhibitors
    Patent number: 8455535
    Abstract: The present invention provides a compound represented by the formula: wherein ring systems A and B, and the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. The compounds of the present invention may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, such as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: June 4, 2013
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Xialing Guo, Shimiao Wang, Julie A. Wurster, Thomas C. Malone